UACT in the News

Press Coverage on UACT’s Work

World Health Organisation (WHO)

• IP Watch. October 13, 2017. “Brief: Cancer Group Recommendations To Ensure Medicines Access in South Africa Draft IP Policy.”
• Governance Now. Shreerupa Mitra-Jha. June 14, 2017 “Making cancer treatment accessible. A recent resolution at the WHO shows it will be a long, winding path before all can afford cancer drugs.”

Xtandi Request

• The Wire. Anoo Bhuyan. March 29, 2018. “US Students Urge UCLA to Drop Proxy Patent Battle for Cancer Drug in India.”
• Alternet. Alexander Zaitchik. March 29, 2018. “Why is UCLA Doing Big Pharma’s Dirty Work in India?“
• LA Times. James Peltz. October 22, 2017. “UCLA’s effort to patent a costly prostate cancer drug in India hurts the poor, critics say.”
• The Wire. Anoo Bhuyan. October 17, 2017. “How the University of California is Fighting Proxy Patent Battle for Expensive Cancer Drug in India.”
• New York Times. Matt Richtel and Andrew Pollack. December 19, 2016. “Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits.”
• LA Times. Melody Petersen. July 6, 2016. “Cancer drug discovered at UCLA sets of takeover fight among biotech companies.”
• Bna.com. John T. Aquino. June 22, 2016. “NIH Won’t ‘March-in’to Allow Generics of Astellas’s Xtandi.”
• FiercePharma.com. Carly Helfand. June 21, 2016. “NIH won’t override patents on Astellas’ pricey Xtandi to bring down prices.”
• Politico.com. Dan Diamond. June 21, 2016. “Where health costs are headed next year.”
• Marioxy Betancourt. June 20, 2016. “U.S. NIH refused petition to override prostate cancer drug patent.”
• Statnews.com. Ed Silverman. June 20, 2016.”NIH rejects petition to override patent on pricey prostate cancer drug.”
• New York Times. Chad Bray and Andrew Pollack. April 28, 2016. ” Sanofi Offers to Buy Drug Maker Medivation for $9.3 Billion.”
• Statnews.com. Ed Silverman. April 28, 2016. “A frustrated Sanofi makes $9.3 billion bid for Medivation and its cancer drug.”
• Forterietimes.ca. Karena Walter. April 26, 2016. “Niagra company offers U.S. cheaper cancer drug.”
• Pharmpro.com. Mike Botta. March 30, 2016.”Lawmakers Seek to Rein in High Cost of Prostate Drug.”
• Nasdaq. Dow Jones Business News. March 29, 2016. “Lawmakers Target Medivation Over Drug Prices.“
• WSJ. Emma Court. March 29, 2016. “Lawmakers Target medication over drug Prices (Including Bernie Sanders).”
• FiercePharma.com. Emily Wasserman. March 29, 2016.”UPDATED: Astellas cancer med Xtandi draws fire as U.S. lawmakers demand a pricing hearing.”
• StatNews.com. Ed Silverman. March 28, 2016. “Sanders, other lawmakers seek NIH hearing to override drug patent.”
• BNA.com John T. Aquino. March 9, 2016. “Congressman says HHS should License generics of Astellas’ Xtandi.”
• Chicago Tribune. Carolyn Y. Johnson. January 14, 2016. “Drugmaker Under fire for taxpayer funded cancer drug that costs $129,269 a year.”

T-DM1 Access in the UK

• The Guardian. Sarah Boseley. October 1, 2015. “Health secretary urged to tear up patent on breast cancer drug.”
• Ars Technica UK. Glyn Moody. October 1, 2015. “Cancer patients call for UK government to override patent on £90,000-a-year drug.”
• Reuters. Ben Hirschler. October 1, 2015. “Call for Britain to over-ride patents on Roche cancer drug.”
• Stat Pharmalot. Ed Silverman. October 1, 2015. “UK patients want government to override Roche patent on cancer drug.”
• FiercePharma. Emily Wasserman. October 1, 2015. “U.K. patient group demands government override Roche’s Kadcyla patents.”
• FirstWord Pharma. Joe Barber. October 1, 2015. “Group calls for UK to grant compulsory licence for Roche’s breast cancer drug Kadcyla.”
• The Pharma Letter. October 2, 2015. “Pressure group seeks compulsory license for biosimilar of Roche’s Kadcyla in UK.”

Trans-Pacific Partnership Agreement

• The New York Times. Weisman, Jonathan. July 30, 2015. “Patent Protection for Drugs Puts Pressure on U.S. in Trade Talks.”
• Al Jazeera America. de Bode, Lisa. July 30, 2015. “Trade deal threatens affordable healthcare for millions, experts say.”

US Trade Pressures

• Korea Biomedical Review. Lee Han-soo. March 12, 2018. “16 Korean, US NGOs criticize PhRMA’s recommendation.”
• The BMJ. Deborah Cohen. November 4, 2014. “US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says.”
• The Hindu. October 31, 2014. “US asked not to pressurise India to reject cancer drug license.”
• The Economic Times. October 31, 2014. “US asked not to pressurise India to reject drug license.”